# LM-108

Source: https://onco.cc/drugs/lm-108/  
OnCo record `lm-108` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LM-108 is an experimental monoclonal antibody from Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical in phase 3 trials for pancreatic ductal adenocarcinoma and gastric & gastro-oesophageal junction cancer, with its target not yet stated publicly.

## Summary

LM-108 is a monoclonal antibody developed by Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical and LaNova Medicines. The sponsor describes its target as CCR8, which OnCo does not yet have a target page for. ClinicalTrials.gov describes the intervention as: LM-108 injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumour sites. Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody. Oxaliplatin is a third-ge. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07362186 (LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma), in pancreatic ductal adenocarcinoma and gastric & gastro-oesophageal junction cancer. The largest, NCT07362186, plans to enrol 400 participants with primary completion expected 2028-08-17. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: monoclonal antibody
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of LM-108: https://clinicaltrials.gov/search?intr=LM-108
- Sponsor page: https://www.lanovamedicines.com/en

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [LaNova Medicines](https://onco.cc/companies/lanova-medicines/), [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)
- trials: [A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors](https://onco.cc/trials/nct05518045/), [LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer](https://onco.cc/trials/nct06387628/), [LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma](https://onco.cc/trials/nct07362186/)

---
JSON: https://onco.cc/api/v1/entities/lm-108.json